Next Article in Journal / Special Issue
Primary Care Physicians’ Knowledge, Attitudes, and Experience with Personal Genetic Testing
Previous Article in Journal
A Theoretical Framework and Conceptual Design for Engaging Children in Therapy at Home—The Design of a Wearable Breathing Trainer
Previous Article in Special Issue
Exploring Predictors of Genetic Counseling and Testing for Hereditary Breast and Ovarian Cancer: Findings from the 2015 U.S. National Health Interview Survey
Open AccessCommunication

Assessing the Joint Value of Genomic-Based Diagnostic Tests and Gene Therapies

1
Manchester Centre for Health Economics, Faculty of Biology, Medicine and Health, The University of Manchester, Oxford Road, Manchester M13 9PL, UK
2
Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA 02215, USA
*
Author to whom correspondence should be addressed.
J. Pers. Med. 2019, 9(2), 28; https://doi.org/10.3390/jpm9020028
Received: 1 April 2019 / Revised: 10 May 2019 / Accepted: 16 May 2019 / Published: 21 May 2019
(This article belongs to the Collection Genomic Medicine and Policy)
Gene therapy is an emerging type of treatment that may aim to provide a cure to individuals with a genetic mutation known to be causative of a specific disease. A diagnosis of the causative mutation must precede treatment with a in vivo gene therapy. Both achieving a genomic-based diagnosis and treatment with a gene therapy may result in substantial expenditures for health care systems. Uncertainties around the health care costs, risks, and benefits derived from diagnosis and treatment with a subsequent gene therapy suggests a need for developing an evidence base, underpinned by opportunity cost, to inform if, and how, these health technologies should be introduced into health care systems funded by finite budgets. This article discusses why current methods to evaluate health technologies (decision-analytic model-based cost-effectiveness analysis from the perspective of a health care system over a lifetime time horizon) are appropriate to quantify the costs and consequences of using genomic-based diagnostic tests and gene therapies in combination, rather than as separate interventions, within clinical practice. Evaluating the economic impact of test-and-treatment strategies will ensure that the opportunity cost of these health technologies is quantified fully for decision-makers who are responsible for allocating limited resources in health care systems. View Full-Text
Keywords: diagnostic test; gene therapy; health economics; opportunity cost; value assessment frameworks diagnostic test; gene therapy; health economics; opportunity cost; value assessment frameworks
Show Figures

Figure 1

MDPI and ACS Style

Gavan, S.P.; Lu, C.Y.; Payne, K. Assessing the Joint Value of Genomic-Based Diagnostic Tests and Gene Therapies. J. Pers. Med. 2019, 9, 28.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop